Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SysmexSSMXF 76 Cash-to-Debt is 0.93 as of Jun. 2026, which is 65% below its 10-year median of 2.64. GuruFocus rates SSMXF with a GF Score™ of 76/100 and a GF Value™ of $17.49 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 842 Medical Devices & Instruments companies, Sysmex ranks worse than 59.5% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Sysmex's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.93.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Sysmexcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Sysmex's Cash-to-Debt or its related term are showing as below:
SSMXF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.93 Med: 2.64 Max: No Debt
Current: 0.93
During the past 13 years, Sysmex's highest Cash to Debt Ratio was No Debt. The lowest was 0.93. And the median was 2.64.
SSMXF's Cash-to-Debt is ranked worse than 59.5% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 1.635
vs SSMXF: 0.93
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Sysmex Cash-to-Debt Related Terms
Sysmex Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Sysmex's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Devices subindustry, Sysmex's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sysmex Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sysmex's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Sysmex's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sysmex (SSMXF) has a Cash-to-Debt of 0.93 as of Jun. 2026. This is 65% below median its historical median of 2.64. Over the past decade, Sysmex's Cash-to-Debt has ranged from 0.93 to 10,000.00. According to the industry distribution chart, Sysmex ranks #501 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 59.5%.
Is Sysmex's Cash-to-Debt too high?
Sysmex's current Cash-to-Debt of 0.93 is 65% below median its 10-year median of 2.64. Over the past 10 years, this metric has ranged from a low of 0.93 to a high of 10,000.00. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. Sysmex's value of 0.93 is 43.1% below this industry median. Based on the distribution chart, Sysmex ranks #501 out of 842 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sysmex has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sysmex's Cash-to-Debt compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Sysmex ranks #501 out of 842 companies for Cash-to-Debt. This places Sysmex in the lower half of its industry. The industry median Cash-to-Debt is 1.64. Sysmex's value of 0.93 is 43.1% below this benchmark. Historically, Sysmex's own Cash-to-Debt has ranged from 0.93 to 10,000.00 over the past decade. While the company's 10-year median is 2.64 vs. the industry median of 1.64, Sysmex has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sysmex's current Cash-to-Debt of 0.93 is 43.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sysmex's current Cash-to-Debt is 0.93, which is 65% below median its own 10-year median of 2.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sysmex stock overvalued right now?
Based on GuruFocus' analysis, Sysmex (SSMXF) is currently considered Significantly Undervalued. The stock's GF Value™ is $17.49, compared to a current price of $11.91 — trading 31.9% below its estimated fair value. The current Cash-to-Debt is 0.93, which is 65% below median its 10-year median of 2.64 and 43.1% below the Medical Devices & Instruments industry median of 1.64. Sysmex's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Sysmex (SSMXF), the current Cash-to-Debt is 0.93 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sysmex (SSMXF) Overvalued in 2026?
Based on GuruFocus' analysis, Sysmex stock appears to be undervalued.
The current stock price of $11.91 is trading 31.9% below its estimated GF Value™ of $17.49.
GuruFocus considers Sysmex to be Significantly Undervalued.
Key valuation signals for SSMXF:
Cash-to-Debt: 0.93 (65% below median its 10-year median of 2.64)
GF Value™: $17.49 vs. price of $11.91 (31.9% below fair value)
Industry Position: 43.1% below the Medical Devices & Instruments median (#501 of 842)
No single metric tells the full story. See the SSMXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sysmex Corp manufactures and sells laboratory testing equipment and reagents. It conducts product development, manufacturing, sales, and service activities in domestic markets, while certain products are also developed, manufactured, and sold through its subsidiaries. The company operates through five reportable segments based on headquarters: Head Office Management, Americas Headquarters, EMEA Headquarters, China Headquarters, and AP Headquarters.
76GF Score
Get the complete analysis for SSMXF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SSMXF has been successfully added to your 
